Badalona

• Study to evaluate reduced antiplatelet therapy after angiolite stent implantation in patients with coronary artery disease Ended recruitment
  2023-507015-35-00 5 2023-10-06 Coronary Artery Disease
• Phase 3, Randomized, Open-Label Study of ARV-471 (PF-07850327) Plus Palbociclib vs Letrozole Plus Palbociclib in Participants With ER(+)/HER … Ended recruitment
  2022-500545-24-00 5 2023-10-04 ER + /HER 2 - Advanced Breast Cancer
• Effect of study drug combined with chemotherapy in patients with locally advanced or metastatic lung cancer with mutated receptor responsibl … Ended recruitment
  2023-504434-22-00 5 2023-10-03 Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous
• Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate … Ended recruitment
  2022-502188-39-00 4 2023-09-27 Dermatitis atopic
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T … Ended recruitment
  2022-501346-30-00 5 2023-09-25 Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) Ended recruitment
  2022-502839-19-00 5 2023-09-14 Obesity
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended recruitment
  2022-502700-78-00 5 2023-09-01 Alopecia areata (AA)
• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Ended recruitment
  2024-515047-31-00 5 2023-08-28 Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma
• An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab … Ended recruitment
  2024-514016-26-00 4 2023-06-22 Multiple Myeloma
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resist … Ended recruitment
  2022-501139-17-01 4 2023-05-05 Aggressive Variant Metastatic Castration Resistant Prostate Cancer
• A study in metastatic breast cancer patients receiving eftilagimod alpha or placebo in combination with a standard chemotherapy (paclitaxel) Ended recruitment
  2024-511023-34-00 10 2023-05-05 HER2-neg/low metastatic breast cancer
• ETOP 22-22 ADEPPT: A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unw … Ended recruitment
  2023-510463-35-00 4 2023-04-26 Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years
• A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer Ended recruitment
  2024-514080-25-00 5 2023-04-21 Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
• ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w … Ended recruitment
  2024-512288-29-00 4 2023-04-11 Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous
• International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended recruitment
  2023-507180-19-00 4 2023-04-05 Cancer
• Study of BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma Ended recruitment
  2022-500687-35-00 9 2023-04-04 Refractory Mantle Cell Lymphoma
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Ended recruitment
  2023-503444-13-00 5 2023-03-29 Relapsed/refractory multiple myeloma

Showing 433–456 of 775 trials